Epidemiology and treatment outcome of ANCA-associated vasculitis in South Korea: a nationwide, population-based cohort study.

OBJECTIVES To investigate the epidemiological features of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in South Korea. METHODS We identified the index cases of GPA and MPA using the 2010-2018 Korean National Health Insurance Service database and the Rare Intractable Disease registry for the entire Korean population. Each disease's incidence and prevalence rates and trends over time were analysed. To assess the impact of disease on morbidity and mortality, a comparator group comprising the general population was established using nearest-neighbour matching by age, sex, income, and comorbidity index, at a 5:1 ratio. Morbidity outcomes included the initiation of renal replacement therapy and admission to the intensive care unit. RESULTS We identified 546 and 795 patients with GPA and MPA, respectively. The incidence rates of both diseases increased with age, with peak incidence rates observed among patients aged ≥70 years. The incidence of MPA increased continuously over time, whereas that of GPA showed no significant changes. During the observation period, 132 (28.7%) and 277 (41.1%) patients in the GPA and MPA groups, respectively, died, which were significantly higher than that in the general population (standardised mortality ratio: 3.53 and 5.58, respectively) and comparator group (hazard ratio: 4.02 and 5.64, respectively). Higher mortality and morbidity rates were observed among patients with MPA than among those with GPA. CONCLUSIONS In South Korea, the incidence of MPA has increased over time. Although both GPA and MPA had high rates of mortality and morbidity, MPA has a poorer prognosis than GPA.

[1]  F. Ferro,et al.  Systemic vasculitis: one year in review 2023. , 2023, Clinical and experimental rheumatology.

[2]  M. Englund,et al.  Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study , 2023, RMD Open.

[3]  R. Luqmani,et al.  Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. , 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Yong-Beom Park,et al.  Secular Trends of Incidence, Prevalence, and Healthcare Economic Burden in ANCA-Associated Vasculitis: An Analysis of the 2002–2018 South Korea National Health Insurance Database , 2022, Frontiers in Medicine.

[5]  Juhee Cho,et al.  Association between the presence of delirium during intensive care unit admission and cognitive impairment or psychiatric problems: the Korean ICU National Data Study , 2022, Journal of Intensive Care.

[6]  Min Chen,et al.  Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients , 2021, BMC Pulmonary Medicine.

[7]  Y. Kim,et al.  Impact of kidney transplantation on the risk of retinal vein occlusion in end-stage renal disease , 2021, Scientific Reports.

[8]  C. Moon,et al.  The cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study. , 2021, Seminars in arthritis and rheumatism.

[9]  J. Stone,et al.  ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry , 2021, The Journal of Rheumatology.

[10]  Su Hwan Lee,et al.  Impact of Intensivist and Nursing Staff on Critically Ill Patient Mortality: A Retrospective Analysis of the Korean NHIS Cohort Data, 2011–2015 , 2020, Yonsei medical journal.

[11]  W. Koldingsnes,et al.  Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. , 2019, Rheumatology.

[12]  J. Stone,et al.  All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. , 2019, Rheumatology.

[13]  J. Yoon,et al.  The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015 , 2019, Orphanet Journal of Rare Diseases.

[14]  D. Misra,et al.  Is granulomatosis with polyangiitis in Asia different from the West? , 2018, International journal of rheumatic diseases.

[15]  J. Esdaile,et al.  Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies , 2017, Annals of the rheumatic diseases.

[16]  P. Merkel,et al.  Trends in Long‐Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Renal Disease , 2016, Arthritis & rheumatology.

[17]  A. Farr,et al.  Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States , 2015, The Journal of Rheumatology.

[18]  N. Basu,et al.  Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  S. Ito,et al.  Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study , 2014, Arthritis Research & Therapy.

[20]  F. Vandergheynst,et al.  ANCA-ASSOCIATED VASCULITIS , 2013, Acta clinica Belgica.

[21]  D. Reid,et al.  The characterisation and determinants of quality of life in ANCA associated vasculitis , 2013, Annals of the rheumatic diseases.

[22]  D. Scott,et al.  The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. , 2012, Rheumatology.

[23]  D. Scott,et al.  Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. , 2011, Rheumatology.

[24]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[25]  L. Jacobsson,et al.  Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.

[26]  D. Scott,et al.  Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  D. Scott,et al.  Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe , 2001, Annals of the rheumatic diseases.

[28]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.